Taro and Alkem to Collaborate on Product Development For U.S. And Other Markets
Posted on: Thursday, 29 December 2005, 09:00 CST
HAWTHORNE, N.Y., Dec. 29, 2005 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) (the "Company") reported today that it has entered into an agreement with Alkem Laboratories Ltd. ("Alkem") under which the companies will develop products jointly for the U.S. and other markets. Details of the agreement have not been disclosed.
"We believe that this strategic arrangement with Alkem will enable Taro to utilize Alkem's substantial pharmaceutical expertise to enhance our competitive position with specific products in the U.S. and other countries," said Samuel Rubinstein, General Manager of the Company.
"We see our alliance with Taro as a very important step in our process of rapid internationalization. Taro is one of our major international partners," said Mr. Samprada Singh, Chairman of Alkem. "We have commonalities of interests and there are numerous opportunities which we are tapping together for future business."
Alkem Laboratories Ltd., established in 1973, is among India's leading pharmaceutical companies. Alkem has a wide range of products encompassing several therapeutic segments. More information is available at www.alkemlabs.com.
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information, please visit www.taro.com.
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the collaboration agreement between Taro and Alkem Laboratories Ltd. Although Taro Pharmaceutical Industries Ltd. believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurance that its expectations will be attained. Factors that could cause actual results to differ include industry and market conditions; slower than anticipated penetration of new markets; the ability of the companies to work together effectively; physician, pharmacist or patient acceptance of any product or products on which Taro and Alkem collaborate; approvals of Alkem's facilities by regulatory authorities; changes in the Company's financial position; regulatory actions; and, other risks detailed from time to time in the Company's SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements speak only as of the date on which they are made. The Company undertakes no obligation to update, change or revise any forward-looking statements, whether as a result of new information, additional or subsequent developments or otherwise.
CONTACT: Taro Pharmaceutical Industries Ltd. Daniel Saks, Vice President, Corporate Affairs (914) 345-9000 ext. 6208
Kevin Connelly, Chief Financial Officer (914) 345-9000 ext. 6338
Copyright © 2005 PrimeZone Media Network, Inc.
Source: PrimeZone Media Network
Related Articles
- Eisai Inc. Enters Copromotion Agreement With Salix Pharmaceuticals, Ltd. For Balsalazide Products
- Adding the Import and Subtracting the Export, the Total U.S. Consumption Value of the Food Product Machinery Manufacturing Industry for 2006 Was $3,622,000,000
- Heinz Announces Preliminary Proxy Voting Results; Looks Forward With Confidence to Executing Its Plans to Increase Shareholder Value
- Ebert Looks Forward to Return to Work
- Service Providers Can Look Forward to Busy Year
- Taiwan "Looks Forward to Better Ties With Japan" After Election
- We Should All Look Forward to a Productive New School Year
- New champion Taylor looking forward to rematch
- Aniston Looks Forward Past 'Friends'
- UK Astronomers Look Forward to Looking Back
 |
 |
User Comments (0)
RSS Feeds